erythromycin has been researched along with Cancer of Kidney in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagalas, V; Balassoulis, G; Chloros, D; Kontakiotis, T; Manika, K; Patakas, D; Porpodis, K; Sichletidis, L; Spyratos, D; Zarogoulidis, K | 1 |
| Jamal, SA; Murphy, GF; Siu, LL; Skorecki, KL; Tobe, SW; Warner, E | 1 |
1 trial(s) available for erythromycin and Cancer of Kidney
| Article | Year |
|---|---|
Vinblastine and erythromycin: an unrecognized serious drug interaction.
Topics: Aged; Carcinoma, Renal Cell; Constipation; Cyclosporine; Drug Synergism; Drug Therapy, Combination; Erythromycin; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Muscle Spasticity; Neutropenia; Pain; Vinblastine | 1995 |
1 other study(ies) available for erythromycin and Cancer of Kidney
| Article | Year |
|---|---|
Efficacy and safety of erythromycin as sclerosing agent in patients with recurrent malignant pleural effusion.
Topics: Adenocarcinoma; Aged; Anti-Bacterial Agents; Breast Neoplasms; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drainage; Erythromycin; Female; Humans; Kidney Neoplasms; Male; Pleural Effusion, Malignant; Pleurodesis; Recurrence; Safety; Sclerosing Solutions; Treatment Outcome | 2008 |